Recombinant therapeutic glycine n-acyltransferase
This invention relates to a method of producing a recombinant enzyme, more particularly, this invention relates to a method of producing water-soluble enzymatically active recombinant glycine N-acyltransferase (GLYAT (E.G. 18.104.22.168)), including the steps of providing a suitable expression host; preparing a vector including a gene for expressing GLYAT in the expression host to form an expression plasmid; transforming the host with the expression plasmid to form an expression system; expressing the GLYAT gene in the expression system; separating the expressed GLYAT from the expression system.
There is a vast and growing body of literature associating deficient detoxification systems to an increased risk of disease, such as cancer, systemic lupus erythematosus, chronic fatigue and Parkinson’s disease. By enhancing the detoxification of individuals with innately low detoxification capacity or individuals that are exposed to chemicals that impair detoxification, the quality of life could be increased. A rationally designed recombinant glycine N-acyltransferase can possibly be used in enzyme supplementation therapy to enhance the detoxification capacity of a range of patients with inherited metabolic diseases and individuals suffering from various forms of pollution or poisoning. An example of this is individuals exposed to exogenous toxins such as workers in the paint industry that are exposed to xylene that competes with aspirin for detoxification.